{"title":"使用临床和病理数据进行肾脏单克隆γ病变风险分层的机器学习","authors":"Giorgio Cazzaniga , Giulia Capitoli , Raffaella Barretta , Andrew Smith , Gisella Vischini , Giuliana Papalia , Federico Alberici , Federica Mescia , Albino Eccher , Jan Ulrich Becker , Maarten Naesens , Lucrezia Furian , Bernd Schröppel , Stefania Galimberti , Fabio Pagni , Vincenzo L'Imperio","doi":"10.1016/j.ekir.2025.05.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The prompt detection of monoclonal gammopathies of renal significance (MGRS) is clinically relevant for the initiation of chemotherapy. Although clinical and laboratory data can suggest the presence of MGRS, renal biopsy still represents the gold standard, despite not always being performed or eventually postponed because it is not deemed useful or informative. In this retrospective study, machine learning (ML) is used to build a tool to assist the prebiopsy risk stratification of MGRS and reinforce the rationale for the histological examination.</div></div><div><h3>Methods</h3><div>The study included a total of 258 patients with monoclonal gammopathy of undetermined significance, of which 168 MGRS cases (65%) and 90 non-MGRS cases (35%) based on the final renal biopsy result.</div></div><div><h3>Results</h3><div>Patients with MGRS were more frequently female (48.2% vs. 28.9%, <em>P</em> = 0.004) and had more frequent Bence Jones proteinuria (73.2% vs. 41.1%, <em>P</em> < 0.001) than non-MGRS cases, with amyloidosis being the most common diagnosis (62%). The ML model achieved an accuracy of 0.79 (95% confidence interval [CI]: 0.67–0.88) and an area under the receiver operating characteristic curve of 0.80 (95% CI: 0.65–0.93) in the validation set. The model is available as a free desktop and Android mobile app (MGRS Interactive Resource for AI-Guided Evaluation, MIRAGE).</div></div><div><h3>Conclusion</h3><div>The ML-based MGRS risk stratification tool can help in the selection of patients with higher probability to have MGRS on renal biopsy, aiming to direct those patients to a complete histological characterization of the disease.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 8","pages":"Pages 2680-2689"},"PeriodicalIF":5.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Machine Learning for Monoclonal Gammopathies of Renal Significance Risk Stratification Using Clinical and Pathology Data\",\"authors\":\"Giorgio Cazzaniga , Giulia Capitoli , Raffaella Barretta , Andrew Smith , Gisella Vischini , Giuliana Papalia , Federico Alberici , Federica Mescia , Albino Eccher , Jan Ulrich Becker , Maarten Naesens , Lucrezia Furian , Bernd Schröppel , Stefania Galimberti , Fabio Pagni , Vincenzo L'Imperio\",\"doi\":\"10.1016/j.ekir.2025.05.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>The prompt detection of monoclonal gammopathies of renal significance (MGRS) is clinically relevant for the initiation of chemotherapy. Although clinical and laboratory data can suggest the presence of MGRS, renal biopsy still represents the gold standard, despite not always being performed or eventually postponed because it is not deemed useful or informative. In this retrospective study, machine learning (ML) is used to build a tool to assist the prebiopsy risk stratification of MGRS and reinforce the rationale for the histological examination.</div></div><div><h3>Methods</h3><div>The study included a total of 258 patients with monoclonal gammopathy of undetermined significance, of which 168 MGRS cases (65%) and 90 non-MGRS cases (35%) based on the final renal biopsy result.</div></div><div><h3>Results</h3><div>Patients with MGRS were more frequently female (48.2% vs. 28.9%, <em>P</em> = 0.004) and had more frequent Bence Jones proteinuria (73.2% vs. 41.1%, <em>P</em> < 0.001) than non-MGRS cases, with amyloidosis being the most common diagnosis (62%). The ML model achieved an accuracy of 0.79 (95% confidence interval [CI]: 0.67–0.88) and an area under the receiver operating characteristic curve of 0.80 (95% CI: 0.65–0.93) in the validation set. The model is available as a free desktop and Android mobile app (MGRS Interactive Resource for AI-Guided Evaluation, MIRAGE).</div></div><div><h3>Conclusion</h3><div>The ML-based MGRS risk stratification tool can help in the selection of patients with higher probability to have MGRS on renal biopsy, aiming to direct those patients to a complete histological characterization of the disease.</div></div>\",\"PeriodicalId\":17761,\"journal\":{\"name\":\"Kidney International Reports\",\"volume\":\"10 8\",\"pages\":\"Pages 2680-2689\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney International Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468024925002943\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney International Reports","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468024925002943","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Machine Learning for Monoclonal Gammopathies of Renal Significance Risk Stratification Using Clinical and Pathology Data
Introduction
The prompt detection of monoclonal gammopathies of renal significance (MGRS) is clinically relevant for the initiation of chemotherapy. Although clinical and laboratory data can suggest the presence of MGRS, renal biopsy still represents the gold standard, despite not always being performed or eventually postponed because it is not deemed useful or informative. In this retrospective study, machine learning (ML) is used to build a tool to assist the prebiopsy risk stratification of MGRS and reinforce the rationale for the histological examination.
Methods
The study included a total of 258 patients with monoclonal gammopathy of undetermined significance, of which 168 MGRS cases (65%) and 90 non-MGRS cases (35%) based on the final renal biopsy result.
Results
Patients with MGRS were more frequently female (48.2% vs. 28.9%, P = 0.004) and had more frequent Bence Jones proteinuria (73.2% vs. 41.1%, P < 0.001) than non-MGRS cases, with amyloidosis being the most common diagnosis (62%). The ML model achieved an accuracy of 0.79 (95% confidence interval [CI]: 0.67–0.88) and an area under the receiver operating characteristic curve of 0.80 (95% CI: 0.65–0.93) in the validation set. The model is available as a free desktop and Android mobile app (MGRS Interactive Resource for AI-Guided Evaluation, MIRAGE).
Conclusion
The ML-based MGRS risk stratification tool can help in the selection of patients with higher probability to have MGRS on renal biopsy, aiming to direct those patients to a complete histological characterization of the disease.
期刊介绍:
Kidney International Reports, an official journal of the International Society of Nephrology, is a peer-reviewed, open access journal devoted to the publication of leading research and developments related to kidney disease. With the primary aim of contributing to improved care of patients with kidney disease, the journal will publish original clinical and select translational articles and educational content related to the pathogenesis, evaluation and management of acute and chronic kidney disease, end stage renal disease (including transplantation), acid-base, fluid and electrolyte disturbances and hypertension. Of particular interest are submissions related to clinical trials, epidemiology, systematic reviews (including meta-analyses) and outcomes research. The journal will also provide a platform for wider dissemination of national and regional guidelines as well as consensus meeting reports.